Wuhan Rhegen Biotechnology Co., Ltd.
1 clinical trials · Sponsor
◉ Watch Wuhan Rhegen Biotechnology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster (NCT05609045) | Wuhan Rhegen Biotechnology Co., Ltd. | 2023-06-01 |
Track Wuhan Rhegen Biotechnology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.